Drugs · acquisition-cost intelligence
Olanzapine
· ingredient olanzapine· OLANZAPINE 15 mg/1; OLANZAPINE 20 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.14333
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other olanzapine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Olanzapine | $0.09035 | −$0.05300 |
| Olanzapine | $0.10950 | −$0.03380 |
| olanzapine | $0.52536 | +$0.38200 |
| Olanzapine Intramuscular | $21.88 | +$21.73 |
| Zyprexa | $33.26 | +$33.11 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 14% · Step therapy 0% · Quantity limit 66% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.